BCR and chronic myelogenous leukemia, BCR-ABL1 positive: However, five CML patients (L1, L5, L13, L19, and L20) showed major molecular response (MMR) reduction of BCR-ABL transcripts less than 0.1%, but CML patients L7, L11, L12, L13, L15, L16, L17, and L22 showed no response against the drug (Figure 9).